Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down

Core Insights - Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 59 cents for Q4 2025, a decline of 22.4% year over year, and missed the Zacks Consensus Estimate by 9.2% [1][7] - The company’s total revenues for Q4 were $977.2 million, a slight decrease of 0.2% year over year, but exceeded the Zacks Consensus Estimate by 1.12% [3][10] - For the full year 2025, adjusted EPS was $1.83, down 24.1% from the previous year [2] Revenue Analysis - Q4 revenues by geography showed a 13.8% decline in the U.S. to $225 million, while Europe saw a 1% increase to $377 million, and Asia Pacific revenues rose 8.3% to $301.2 million [4] - The BSI BioSpin segment revenues fell 2% to $267 million, while BSI CALID revenues increased by 3.4% to $331.6 million [4] - Total revenues for 2025 reached $3.44 billion, reflecting a 2.1% increase from the previous year [3] Margin Performance - Gross profit decreased by 8.9% to $449.2 million, with gross margin contracting by 439 basis points to 46% due to an 8.6% rise in the cost of revenues [5][10] - Adjusted operating profit was $102.4 million, down 27.7% year over year, with adjusted operating margin contracting by 398 basis points to 10.5% [5] Financial Position - At the end of Q4 2025, Bruker had cash and cash equivalents of $298.8 million, an increase from $183.4 million at the end of 2024 [6] - Long-term debt at the end of Q4 2025 was $1.87 billion, down from $2.09 billion at the end of Q4 2024 [8] 2026 Guidance - Bruker provided guidance for 2026, expecting revenues between $3.57 billion and $3.60 billion, indicating a year-over-year growth of 4% to 5% [9] - Adjusted EPS for 2026 is projected to be in the range of $2.10 to $2.15, representing an increase of 15% to 17% year over year [9] Overall Assessment - The company ended Q4 2025 with mixed results, as earnings missed estimates while revenues surpassed them [10] - Margins were negatively impacted by lower volume, unfavorable mix, tariffs, and currency headwinds [10] - Despite challenges, Bruker’s innovation efforts showed promise, with expectations for improved contributions from the BEST segment in 2026 [11]